glp 1 economist Whether those now taking GLP-1 drugs preventatively will live to regret doing that or, conversely, will live long enough not to, remains to be seen https://econ.st/3NdZe4k Illustration: Cristina Spanò Weight-loss drugs are no match
Description
The science behind 24% weight loss results explained.
Patients who reduced the frequency of GLP-1 dosing (from weekly to every other week) were able to maintain their weight loss and metabolic syndrome gains, as reported in this case series
Semaglutide and tirzepatide programs with nutrition coaching
Results Patients with a high cumulative dose of GLP-1 agonist are associated with a higher risk of developing drug-induced pancreatitis associated with GLP-1 agonists, indicated by a statistically significant odds ratio
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular and kidney benefits in the general population with type 2 diabetes mellitus (T2DM), evidence regarding their effects in diabetic KTRs is limited
